HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.

AbstractOBJECTIVE:
To examine the effectiveness of switching patients to lurasidone using 3 different dosing strategies.
METHOD:
Adults with DSM-IV-defined schizophrenia or schizoaffective disorder in a nonacute phase of illness were randomized to 1 of 3 lurasidone dosing regimens for the initial 2 weeks of the study: (1) 40 mg/d for 2 weeks; (2) 40 mg/d for 1 week, increased to 80 mg/d on day 8 for week 2 (up-titration group); and (3) 80 mg/d for 2 weeks. Lurasidone was then flexibly dosed (40-120 mg/d) for the subsequent 4 weeks of the study. The preswitch antipsychotic agent was tapered by day 7 to 50% of the original dose and discontinued by the end of week 2. Subjects were stratified on the basis of whether the primary preswitch antipsychotic medication was classified as "sedating" (olanzapine or quetiapine) or "nonsedating" (all other antipsychotics). The primary outcome measure was time to treatment failure, defined as any occurrence of insufficient clinical response, exacerbation of underlying disease, or discontinuation due to an adverse event. The study was conducted from June 2010 to May 2011.
RESULTS:
Of 240 subjects treated in this study, 86 (35.8%) were treated with an antecedent sedating antipsychotic, and 154 (64.2%) were treated with an antecedent nonsedating antipsychotic. Nineteen (7.9%) of the 240 patients experienced treatment failure. No clinically relevant differences were observed when the 3 randomized switch groups were compared. Treatment failure rates were 10/86 (11.6%) versus 9/154 (5.8%) among subjects who had been receiving a preswitch sedating versus nonsedating antipsychotic medication, respectively. Consistent with prior studies of lurasidone, there was no signal for clinically relevant adverse changes in body weight, glucose, insulin, lipids, or prolactin; mean improvements in weight and lipids were observed. Movement disorder rating scales did not demonstrate meaningful changes. The incidence of akathisia as an adverse event was 12.5%; only 1 subject (0.4%) discontinued due to akathisia.
CONCLUSIONS:
Switching patients to lurasidone can be successfully accomplished by starting at 40 mg/d for 2 weeks, or 80 mg/d for 2 weeks, or 40 mg/d for 1 week followed by 80 mg/d the second week.
TRIAL REGISTRATION:
ClinicalTrials.gov identifier: NCT01143077.
AuthorsJoseph P McEvoy, Leslie Citrome, David Hernandez, Josephine Cucchiaro, Jay Hsu, Andrei Pikalov, Antony Loebel
JournalThe Journal of clinical psychiatry (J Clin Psychiatry) Vol. 74 Issue 2 Pg. 170-9 (Feb 2013) ISSN: 1555-2101 [Electronic] United States
PMID23473350 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© Copyright 2013 Physicians Postgraduate Press, Inc.
Chemical References
  • Antipsychotic Agents
  • Dibenzothiazepines
  • Isoindoles
  • Thiazoles
  • Benzodiazepines
  • Quetiapine Fumarate
  • Olanzapine
  • Lurasidone Hydrochloride
Topics
  • Adult
  • Akathisia, Drug-Induced (etiology)
  • Antipsychotic Agents (administration & dosage, adverse effects, therapeutic use)
  • Benzodiazepines (therapeutic use)
  • Dibenzothiazepines (therapeutic use)
  • Drug Administration Schedule
  • Female
  • Humans
  • Isoindoles (administration & dosage, adverse effects, therapeutic use)
  • Lurasidone Hydrochloride
  • Male
  • Olanzapine
  • Psychotic Disorders (drug therapy)
  • Quetiapine Fumarate
  • Schizophrenia (drug therapy)
  • Thiazoles (administration & dosage, adverse effects, therapeutic use)
  • Time Factors
  • Treatment Failure
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: